1,153 results on '"Lacouture, Mario E."'
Search Results
152. Skin adverse events of anti-cancer treatments: an examination of drug-adverse events associations.
153. The emergence of supportive oncodermatology: The study of dermatologic adverse events to cancer therapies
154. The Efficacy and Safety of Panitumumab Administered Concomitantly With FOLFIRI or Irinotecan in Second-Line Therapy for Metastatic Colorectal Cancer: The Secondary Analysis From STEPP (Skin Toxicity Evaluation Protocol With Panitumumab) by KRAS Status
155. Noninvasive Genomic Characterization of Patients with Nonsclerotic and Superficially Sclerotic Chronic Cutaneous Graft-Versus-Host Disease Identified a Novel Gene Signature in Responders to Ruxolitinib Cream
156. Interim Results of a Pilot, Prospective, Randomized, Double-Blinded, Vehicle-Controlled Trial on Safety and Efficacy of a Topical Inhibitor of Janus Kinase 1/2 (Ruxolitinib INCB018424 Phosphate 1.5% Cream) for Non-Sclerotic and Superficially Sclerotic Chronic Cutaneous Graft-Versus-Host Disease
157. Management of Dermatologic Events Associated With the Nectin-4-directed Antibody-Drug Conjugate Enfortumab Vedotin
158. A survey study of prevention and treatment patterns by academic and community oncologists for hand-foot skin reaction associated with vascular endothelial growth factor receptor inhibitor (VEGFRi) therapy.
159. Part 1 results from NOVA-II, a randomized, double-blind, vehicle-controlled phase II study evaluating the safety and efficacy of OQL011 on VEGFR inhibitor associated hand-foot skin reaction in cancer patients.
160. Development of prediction tools for diarrhea and rash in breast cancer patients receiving lapatinib in combination with capecitabine
161. EMPACT syndrome: limited evidence despite a high-risk cohort
162. Ado-trastuzumab emtansine-associated telangiectasias in metastatic breast cancer: a case series
163. Beyond the dose-limiting toxicity period: Dermatologic adverse events of patients on phase 1 trials of the Cancer Therapeutics Evaluation Program
164. Beyond Steroids: Immunosuppressants in Steroid-Refractory or Resistant Immune-Related Adverse Events
165. Phase 1/2 Study of Topical Submicron Particle Paclitaxel for Cutaneous Metastases of Breast Cancer
166. Dermatologic Events Associated with the Anti-CCR4 Antibody Mogamulizumab: Characterization and Management
167. Corrigendum to ‘SJS/TEN 2019: From science to translation’ [J. Dermatol. Sci. 98/1 (2020) 2–12]
168. Immune checkpoint inhibitors in patients with pre-existing psoriasis: safety and efficacy
169. Incidence of dermatologic adverse events in patients with cancer treated with concurrent immune checkpoint inhibitors and radiation therapy: A systematic review and meta-analysis
170. Targeting Mutant BRAF in Relapsed or Refractory Hairy-Cell Leukemia
171. Melanoma and non-melanoma skin cancers in hairy cell leukaemia: a Surveillance, Epidemiology and End Results population analysis and the 30-year experience at Memorial Sloan Kettering Cancer Center
172. Reply to: “Skin moisturization for xerosis related to targeted anticancer therapies”
173. Dermatologic adverse events in pediatric patients receiving targeted anticancer therapies: A pooled analysis
174. Clinico-morphological features of BRAF inhibition–induced proliferative skin lesions in cancer patients
175. Risk of Hand-Foot Skin Reaction with the Multitargeted Kinase Inhibitor Sunitinib in Patients with Renal Cell and Non–Renal Cell Carcinoma: A Meta-analysis
176. Clinical practice guidelines for the prevention and treatment of acute and late radiation reactions from the MASCC Skin Toxicity Study Group
177. Dermatologic Adverse Events to Targeted Therapies in Lower GI Cancers: Clinical Presentation and Management
178. Risk of hand-foot skin reaction with the novel multikinase inhibitor regorafenib: a meta-analysis
179. Impact of Dermatologic Adverse Events on Quality of Life in 283 Cancer Patients: A Questionnaire Study in a Dermatology Referral Clinic
180. Experiences with the FACT-EGFRI-18 instrument in EGFRI-associated mucocutaneous adverse events
181. Dermatological Adverse Events from BRAF Inhibitors: A Growing Problem
182. The risk of hand-foot skin reaction to axitinib, a novel VEGF inhibitor: a systematic review of literature and meta-analysis
183. Spectrum of ocular toxicities from epidermal growth factor receptor inhibitors and their intermediate-term follow-up: a five-year review
184. The development of a Functional Assessment of Cancer Therapy (FACT) questionnaire to assess dermatologic symptoms associated with epidermal growth factor receptor inhibitors (FACT-EGFRI-18)
185. Dermatologic Infections in Cancer Patients
186. 27891 Safety and efficacy of an Avena sativa (oat) skin care regimen for therapy-related xerosis and pruritus in adult oncology patients undergoing systemic cancer treatments
187. Risk of rash with the anti-HER2 dimerization antibody pertuzumab: a meta-analysis
188. The risk of hand foot skin reaction to pazopanib, a novel multikinase inhibitor: a systematic review of literature and meta-analysis
189. Dermatologic side effects associated with the MEK 1/2 inhibitor selumetinib (AZD6244, ARRY-142886)
190. Skin care management in cancer patients: an evaluation of quality of life and tolerability
191. Pegylated liposomal doxorubicin-associated hand–foot syndrome: Recommendations of an international panel of experts
192. Completeness in the Reporting of Dermatologic Adverse Drug Reactions Associated with Monoclonal Antibody Epidermal Growth Factor Receptor Inhibitors in Phase II and III Colorectal Cancer Clinical Trials
193. Unanticipated toxicities from anticancer therapies: Survivors’ perspectives
194. A proposed EGFR inhibitor dermatologic adverse event-specific grading scale from the MASCC skin toxicity study group
195. Bullous disorders associated with PD-1 and PD-L1 inhibitors: Pharmacovigilance analysis of the United States Food and Drug Administration Adverse Event Reporting System from the Research on Adverse Drug Events And Reports Program
196. Differential Radiation Dermatitis in Native Skin and an Autologous Transplanted Myocutaneous Flap
197. Dermoscopic Findings in Cutaneous Metastases
198. Dermatologic issues in adult survivors of childhood cancer
199. Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immune checkpoint inhibitor-related adverse events
200. A phase II study to evaluate the safety and efficacy of OQL011 on VEGFR inhibitor-associated hand-foot-skin reaction in cancer patients.
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.